Compare LUMN & TECH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LUMN | TECH |
|---|---|---|
| Founded | 1968 | 1976 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7B | 9.1B |
| IPO Year | 1994 | 1995 |
| Metric | LUMN | TECH |
|---|---|---|
| Price | $8.02 | $59.10 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | $7.25 | ★ $71.82 |
| AVG Volume (30 Days) | ★ 12.9M | 2.6M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 0.62% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.81 |
| Revenue | ★ $12,402,000,000.00 | $1,219,635,000.00 |
| Revenue This Year | N/A | $2.49 |
| Revenue Next Year | N/A | $6.40 |
| P/E Ratio | ★ N/A | $72.67 |
| Revenue Growth | N/A | ★ 5.23 |
| 52 Week Low | $3.37 | $43.20 |
| 52 Week High | $11.95 | $72.16 |
| Indicator | LUMN | TECH |
|---|---|---|
| Relative Strength Index (RSI) | 39.00 | 64.85 |
| Support Level | $7.40 | $57.46 |
| Resistance Level | $8.42 | $62.88 |
| Average True Range (ATR) | 0.51 | 2.20 |
| MACD | -0.15 | 0.58 |
| Stochastic Oscillator | 18.61 | 88.22 |
Lumen Technologies is one of the largest telecommunications carriers serving global enterprises. The merger with Level 3 in 2017, the 2022 divestiture of much of its local phone business in rural areas, and the 2026 sale of its remaining consumer fiber network to AT&T have shifted the company's operations away from the legacy consumer business and toward enterprise services, which account for about 85%-90% of revenue. Lumen offers businesses a full suite of communications services, providing colocation and data center services, data transportation, phone service, and internet access.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.